Literature DB >> 24239651

Blood and Marrow Transplant Clinical Trials Network: progress since the State of the Science Symposium 2007.

James L M Ferrara1.   

Abstract

Outcomes of hematopoietic cell transplantation continue to improve. New techniques have reduced transplant toxicities, and there are new sources of hematopoietic stem cells from related and unrelated donors. In June 2007, the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) convened a State of the Science Symposium (SOSS) in Ann Arbor and identified 11 high priority clinical trials for the network to pursue. This article reviews both the status of those trials and the record of achievement of the BMT CTN as it convenes another SOSS in Grapevine, Texas in February 2014.
Copyright © 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute lymphocytic leukemia; Acute myeloid leukemia; Biomarkers; Cell therapy; Chronic lymphocytic leukemia; Clinical Trials Network; Clinical trials; Crohn's disease; Graft-versus-host disease; Hemaphogocytic lymphohistiocytosis; Hematopoietic cell transplantation; Quality of life; T cell lymphoma

Mesh：

Year:  2013        PMID： 24239651      PMCID： PMC4957643          DOI： 10.1016/j.bbmt.2013.11.006

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


  35 in total

1.  Effects of aerobic exercise on the physical performance and incidence of treatment-related complications after high-dose chemotherapy.

Authors:  F Dimeo; S Fetscher; W Lange; R Mertelsmann; J Keul
Journal:  Blood       Date:  1997-11-01       Impact factor: 22.113

2.  Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease.

Authors:  Yu Oyama; Robert M Craig; Ann E Traynor; Kathleen Quigley; Laisvyde Statkute; Amy Halverson; Mary Brush; Larissa Verda; Barbara Kowalska; Nela Krosnjar; Morris Kletzel; Peter F Whitington; Richard K Burt
Journal:  Gastroenterology       Date:  2005-03       Impact factor: 22.682

Review 3.  New prognostic markers in CLL.

Authors:  Emili Montserrat
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2006

4.  Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

Authors:  Jan J Cornelissen; Wim L J van Putten; Leo F Verdonck; Matthias Theobald; Emanuel Jacky; Simon M G Daenen; Marinus van Marwijk Kooy; Pierre Wijermans; Harry Schouten; Peter C Huijgens; Hans van der Lelie; Martin Fey; Augustin Ferrant; Johan Maertens; Alois Gratwohl; Bob Lowenberg
Journal:  Blood       Date:  2007-01-09       Impact factor: 22.113

5.  The thymus and prolonged administration of cyclosporine. Irreversible immunopathologic changes associated with autologous pseudo-graft-versus-host disease.

Authors:  T Shinozawa; W E Beschorner; A D Hess
Journal:  Transplantation       Date:  1990-07       Impact factor: 4.939

6.  Relaxation and imagery and cognitive-behavioral training reduce pain during cancer treatment: a controlled clinical trial.

Authors:  Karen L Syrjala; Gary W Donaldson; Martha W Davis; Michael E Kippes; John E Carr
Journal:  Pain       Date:  1995-11       Impact factor: 6.961

Review 7.  Graft-versus-host reactions and disease.

Authors:  G W Santos; A D Hess; G B Vogelsang
Journal:  Immunol Rev       Date:  1985-12       Impact factor: 12.988

Review 8.  Haemopoietic stem cell transplantation in autoimmune diseases: a European perspective.

Authors:  R E Hough; J A Snowden; N M Wulffraat
Journal:  Br J Haematol       Date:  2005-02       Impact factor: 6.998

9.  Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy.

Authors:  F C Dimeo; R D Stieglitz; U Novelli-Fischer; S Fetscher; J Keul
Journal:  Cancer       Date:  1999-05-15       Impact factor: 6.860

10.  Pilot study of a home-based aerobic exercise program for sedentary cancer survivors treated with hematopoietic stem cell transplantation.

Authors:  R W Wilson; P B Jacobsen; K K Fields
Journal:  Bone Marrow Transplant       Date:  2005-04       Impact factor: 5.483
View more
  7 in total

Review 1.  The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation.

Authors: 
Journal:  Biol Blood Marrow Transplant       Date:  2016-07-11       Impact factor: 5.742

2.  NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT.

Authors:  Mobin A Karimi; Jerrod L Bryson; Lee P Richman; Andrew D Fesnak; Theresa M Leichner; Atsushi Satake; Robert H Vonderheide; David H Raulet; Ran Reshef; Taku Kambayashi
Journal:  Blood       Date:  2015-03-18       Impact factor: 22.113

3.  Blood and marrow transplant clinical trials network state of the Science Symposium 2014.

Authors:  Frederick R Appelbaum; Claudio Anasetti; Joseph H Antin; Harold Atkins; Stella Davies; Steven Devine; Sergio Giralt; Helen Heslop; Ginna Laport; Stephanie J Lee; Brent Logan; Marcelo Pasquini; Michael Pulsipher; Edward Stadtmauer; John R Wingard; Mary M Horowitz
Journal:  Biol Blood Marrow Transplant       Date:  2014-10-15       Impact factor: 5.742

4.  Quality control and assurance in hematopoietic stem cell transplantation data registries in Japan and other countries.

Authors:  Yachiyo Kuwatsuka
Journal:  Int J Hematol       Date:  2015-11-13       Impact factor: 2.490

5.  Participation in clinical research: perspectives of adult patients and parents of pediatric patients undergoing hematopoietic stem cell transplantation.

Authors:  Florian Keusch; Rohini Rao; Lawrence Chang; James Lepkowski; Pavan Reddy; Sung Won Choi
Journal:  Biol Blood Marrow Transplant       Date:  2014-06-24       Impact factor: 5.742

6.  Targeting SLP76:ITK interaction separates GVHD from GVL in allo-HSCT.

Authors:  Mahinbanu Mammadli; Weishan Huang; Rebecca Harris; Hui Xiong; Samuel Weeks; Adriana May; Teresa Gentile; Jessica Henty-Ridilla; Adam T Waickman; Avery August; Alaji Bah; Mobin Karimi
Journal:  iScience       Date:  2021-03-11

7.  Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT.

Authors:  Mahinbanu Mammadli; Weishan Huang; Rebecca Harris; Aisha Sultana; Ying Cheng; Wei Tong; Jeffery Pu; Teresa Gentile; Shanti Dsouza; Qi Yang; Alaji Bah; Avery August; Mobin Karimi
Journal:  Front Immunol       Date:  2020-11-26       Impact factor: 7.561
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.